Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-08-19

Study Completion Date

2014-08-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized phase I/II trial studies the side effects and best dose of lapatinib ditosylate and to see how well it works in treating patients with ductal breast carcinoma in situ. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer

NCT00450892

Breast Cancer

COMPLETED PHASE1/PHASE2

Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.

NCT00524303

Neoplasms, Breast

COMPLETED PHASE2

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

NCT00482391

Breast Cancer

COMPLETED PHASE2

Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer

NCT00820872

Breast Cancer

COMPLETED PHASE2

Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast

NCT00788112

Breast Cancer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. Determine whether lapatinib (lapatinib ditosylate) therapy at the dose of 1000 mg results in a statistically significantly lower rate of proliferation in ductal carcinoma in situ (DCIS) breast cancer cells as measured by Ki67 when compared to placebo.

II. Determine the toxicity profile and frequency of adverse events in women with DCIS breast cancer taking lapatinib at 1000 mg as compared to women taking placebo.

SECONDARY OBJECTIVES:

I. Determine whether lapatinib treatment affects the incidence of DCIS seen at the time of surgical excision.

II. Determine whether treatment with lapatinib will modulate breast tissue histology or the expression of specific biomarkers in normal and DCIS breast cancer cells.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive lapatinib ditosylate orally (PO) once daily (QD) for 2-6 weeks until the time of surgery.

ARM II: Patients receive placebo PO QD for 2-6 weeks until the time of surgery.

After completion of study treatment, patients are followed for 4-5 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ductal Breast Carcinoma In Situ HER2/Neu Positive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I (lapatinib ditosylate)

Patients receive lapatinib ditosylate PO once QD for 2-6 weeks until the time of surgery.

Group Type EXPERIMENTAL

Laboratory Biomarker Analysis

Intervention Type OTHER

Correlative studies

Lapatinib Ditosylate

Intervention Type DRUG

Given PO

Arm II (placebo)

Patients receive placebo PO QD for 2-6 weeks until the time of surgery.

Group Type PLACEBO_COMPARATOR

Laboratory Biomarker Analysis

Intervention Type OTHER

Correlative studies

Placebo

Intervention Type OTHER

Given PO

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Laboratory Biomarker Analysis

Correlative studies

Intervention Type OTHER

Lapatinib Ditosylate

Given PO

Intervention Type DRUG

Placebo

Given PO

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tykerb placebo therapy PLCB sham therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants must be premenopausal or postmenopausal
* Participants must have a diagnosis of ductal carcinoma in situ made by core needle biopsy
* The DCIS cells must have high expression of human epidermal growth factor receptor 2 (erbB2) (3+ by immunohistochemical staining or amplification by fluorescence in situ hybridization \[FISH\]), and/or have detectable expression of epidermal growth factor receptor (EGFR) (1+ or more by immunohistochemical staining)
* All participants must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
* Individuals with a diagnosis of breast cancer, non-melanoma skin cancer, cervical cancer in situ, or early bladder cancer are eligible if they have not been treated with chemotherapy, biological therapy, or breast radiotherapy to the breast currently affected by DCIS within one year; in addition, individuals with a diagnosis of breast cancer may not have used tamoxifen, raloxifene, or other antiestrogen compounds within three months of study day 1
* If subjects are of reproductive potential, they must agree to use a reliable contraceptive method or be sexually abstinent; subjects must fulfill these conditions beginning at the time of starting study medications and ending one month after study termination
* Negative serum pregnancy test (beta-human chorionic gonadotropin \[HCG\]) at baseline (within 30 days of day 0) for women of child bearing potential
* Serum creatinine =\< 1.5 times the institution?s upper limit of normal
* Total bilirubin =\< 1.5 times the institution's upper limits of normal
* Serum glutamic oxaloacetic transaminase (SGOT) =\< 1.5 times the institution's upper limits of normal
* Alkaline phosphatase =\< 1.5 times the institution's upper limits of normal
* Albumin =\< 1.5 times the institution's upper limits of normal
* White blood cells (WBC) \> 4.0 k/uL
* Platelet count \> 100,000/uL
* Hematocrit of \> 30%
* Cardiac ejection fraction within normal limits for the institution by multi gated acquisition scan (MUGA) scan or normal cardiac ultrasound (defined as within the upper limit of normal \[ULN\] for the institution)
* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
* Willingness to refrain from donating blood to others during the study

Exclusion Criteria

* Individuals are ineligible if they have either active cancer or a prior history of malignancies other than (e.g., breast cancer, skin cancer \[basal or squamous cell carcinoma\], cervical cancer in situ, or early bladder cancer \[preinvasive transitional cell carcinoma of the bladder\]) within the past five years
* Participants are ineligible if they are currently being treated with tamoxifen, raloxifene, or with aromatase inhibitors (letrozole, anastrozole, exemestane)
* Individuals are ineligible if they have received chemotherapy, biological therapy (e.g., Herceptin), or radiotherapy for the treatment of any cancer within 1 year or if they have received tamoxifen, raloxifene, letrozole, anastrozole, or exemestane therapy within 3 months of study day 1
* Individuals currently receiving anticoagulation therapy (e.g., Coumadin) are ineligible
* Blood urea nitrogen \[BUN\] \> 1.5 x ULN or
* Creatinine \[Cr\] \> 1.5 x ULN
* SGOT \> 1.5 x ULN
* Serum glutamate pyruvate transaminase (SGPT) \> 1.5 x ULN
* Alkaline phosphatase \> 1.5 x ULN
* Bilirubin \> 1.5x ULN
* Individuals who are currently participating in a study of an investigational drug
* Pregnancy, lactation or unwillingness to use a reliable contraceptive method in women of childbearing potential
* Severe underlying chronic illness or disease, such as uncontrolled diabetes
* Individuals with known congestive heart disease or previous myocardial infarction are ineligible
* Patients taking any prohibited medications
* Individuals with hypokalemia or hypomagnesemia are ineligible unless these conditions are corrected to within normal limits before starting drug
* Individuals with congenital long QT syndrome or baseline QTcF intervals \> 480 msec on electrocardiogram (EKG)
* Individuals taking anti-arrhythmics, beta blockers, or other medications that may lead to QT prolongation
* Individuals who have received a cumulative dose of anthracycline therapy greater than 500 mg/m\^2 are ineligible

Minimum Eligible Age

21 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Powel Brown

Role: PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, United States

Site Status

M D Anderson Cancer Center

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States